---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070287"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T14:02:46.948769+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Larimar Therapeutics holds 2025 Annual Meeting; all proposals pass

## Summary
- Thomas E. Hamilton elected Class II director with 46.5M votes for, 4.3M withheld.
- Advisory say-on-pay approved: 49.2M for, 1.4M against, 0.2M abstain.
- Ratification of PricewaterhouseCoopers as auditor for 2025: 57.7M for, 10.9K against.
- No other material proposals; all votes passed.

## SEC filing metadata
- accession: 0000950170-25-070287
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017025070287/0000950170-25-070287-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017025070287/lrmr-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070287
- JSON: https://secwatch.observer/filing/0000950170-25-070287.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070287.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.